M Killer-Oberpfalzer1, N Kocer2, C J Griessenauer3,4, H Janssen5, T Engelhorn6, M Holtmannspötter7, J H Buhk8, T Finkenzeller5, G Fesl9, J Trenkler10, W Reith11, A Berlis12, K Hausegger13, M Augustin14, C Islak2, B Minnich15, M Möhlenbruch16. 1. From the Research Institute of Neurointervention/Department of Neurology (M.K.-O., C.J.G.), Paracelsus Medical University, Salzburg, Austria m.killer@salk.at. 2. Department of Neuroradiology (N.K., C.I.), Cerrahpasa Medical School, Istanbul University, Turkey. 3. From the Research Institute of Neurointervention/Department of Neurology (M.K.-O., C.J.G.), Paracelsus Medical University, Salzburg, Austria. 4. Department of Neurosurgery (C.J.G.), Geisinger Health, Danville, Pennsylvania. 5. Institute of Radiology and Neuroradiology (H.J., T.F.), Klinikum Nuernberg Sued, Paracelsus Medical University, Nuernberg, Germany. 6. Department of Neuroradiology (T.E.), University Hospital, Erlangen, Germany. 7. Department of Diagnostic Radiology (M.H.), Rigshospitalet, Copenhagen, Denmark. 8. Department of Neuroradiology (J.H.B.), University Hospital Hamburg, Eppendorf, Germany. 9. Department of Neuroradiology (G.F.), Klinikum Grosshadern, University of Munich, Munich, Germany. 10. Department of Neuroradiology (J.T.), Kepler Universitätsklinikum, Linz, Austria. 11. Klinik für Diagnostische und Interventionelle Neuroradiologie (W.R.), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. 12. Klinik für Diagnostische Radiologie und Neuroradiologie (A.B.), Klinikum Augsburg, Augsburg, Germany. 13. Department of Diagnostic and Interventional Radiology (K.H.), Klinikum Klagenfurt, Klagenfurt, Austria. 14. Department of Radiology (M.A.), University Hospital, Graz, Austria. 15. Department of Cell Biology and Physiology (B.M.), Universität Salzburg, Salzburg, Austria. 16. Department of Neuroradiology (M.M.), Universitätsklinikum Heidelberg, Heidelberg, Germany.
Abstract
BACKGROUND AND PURPOSE: Endoluminal reconstruction with flow-diverting stents represents a widely accepted technique for the treatment of complex intracranial aneurysms. This European registry study analyzed the initial experience of 15 neurovascular centers with the Flow-Redirection Intraluminal Device (FRED) system. MATERIALS AND METHODS: Consecutive patients with intracranial aneurysms treated with the FRED between February 2012 and March 2015 were retrospectively reviewed. Complications and adverse events, transient and permanent morbidity, mortality, and occlusion rates were evaluated. RESULTS: During the defined study period, 579 aneurysms in 531 patients (median age, 54 years; range, 13-86 years) were treated with the FRED. Seven percent of patients were treated in the acute phase (≤3 days) of aneurysm rupture. The median aneurysm size was 7.6 mm (range, 1-36.6 mm), and the median neck size 4.5 mm (range, 1-30 mm). Angiographic follow-up of >3 months was available for 516 (89.1%) aneurysms. There was progressive occlusion witnessed with time, with complete occlusion in 18 (20%) aneurysms followed for up to 90 ± 14 days, 141 (82.5%) for 180 ± 20 days, 116 (91.3%) for 1 year ± 24 days, and 122 (95.3%) aneurysms followed for >1 year. Transient and permanent morbidity occurred in 3.2% and 0.8% of procedures, respectively. The overall mortality rate was 1.5%. CONCLUSIONS: This retrospective study in real-world patients demonstrated the safety and efficacy of the FRED for the treatment of intracranial aneurysms. In most cases, treatment with a single FRED resulted in complete angiographic occlusion at 1 year.
BACKGROUND AND PURPOSE: Endoluminal reconstruction with flow-diverting stents represents a widely accepted technique for the treatment of complex intracranial aneurysms. This European registry study analyzed the initial experience of 15 neurovascular centers with the Flow-Redirection Intraluminal Device (FRED) system. MATERIALS AND METHODS: Consecutive patients with intracranial aneurysms treated with the FRED between February 2012 and March 2015 were retrospectively reviewed. Complications and adverse events, transient and permanent morbidity, mortality, and occlusion rates were evaluated. RESULTS: During the defined study period, 579 aneurysms in 531 patients (median age, 54 years; range, 13-86 years) were treated with the FRED. Seven percent of patients were treated in the acute phase (≤3 days) of aneurysm rupture. The median aneurysm size was 7.6 mm (range, 1-36.6 mm), and the median neck size 4.5 mm (range, 1-30 mm). Angiographic follow-up of >3 months was available for 516 (89.1%) aneurysms. There was progressive occlusion witnessed with time, with complete occlusion in 18 (20%) aneurysms followed for up to 90 ± 14 days, 141 (82.5%) for 180 ± 20 days, 116 (91.3%) for 1 year ± 24 days, and 122 (95.3%) aneurysms followed for >1 year. Transient and permanent morbidity occurred in 3.2% and 0.8% of procedures, respectively. The overall mortality rate was 1.5%. CONCLUSIONS: This retrospective study in real-world patients demonstrated the safety and efficacy of the FRED for the treatment of intracranial aneurysms. In most cases, treatment with a single FRED resulted in complete angiographic occlusion at 1 year.
Authors: Hannes Luecking; Arnd Doerfler; Philipp Goelitz; Philip Hoelter; Tobias Engelhorn; Stefan Lang Journal: Interv Neuroradiol Date: 2019-10-09 Impact factor: 1.610
Authors: C J Griessenauer; M A Möhlenbruch; P Hendrix; C Ulfert; C Islak; M Sonnberger; T Engelhorn; E Müller-Thies-Broussalis; T Finkenzeller; M Holtmannspötter; J-H Buhk; W Reith; A Simgen; H Janssen; N Kocer; M Killer-Oberpfalzer Journal: AJNR Am J Neuroradiol Date: 2020-02-27 Impact factor: 3.825
Authors: Christian A Taschner; Christian Paul Stracke; Franziska Dorn; Krzysztof Bartosz Kadziolka; Kornelia Kreiser; László Solymosi; Mirko Pham; Jan Hendrik Buhk; Bernd Turowski; Wolfgang Reith; Samer Elsheikh; Stephan Meckel; Hendrik Janssen; Alexander Hammer; Oliver Beuing; Olav Jansen; Horst Urbach; Michael Knauth; Carolin Jenkner; René Chapot Journal: J Neurointerv Surg Date: 2020-09-08 Impact factor: 5.836
Authors: Hannes Luecking; Tobias Struffert; Philipp Goelitz; Tobias Engelhorn; Sebastian Brandner; Joji B Kuramatsu; Stefan Lang; Manuel Schmidt; Arnd Doerfler Journal: Clin Neuroradiol Date: 2020-05-08 Impact factor: 3.649